Conventional disease-modifying agents in rheumatoid arthritis - a review of their current use and role in treatment algorithms.
disease-modifying antirheumatic drug
leflunomide
methotrexate
rheumatoid arthritis
Journal
Reumatologia
ISSN: 0034-6233
Titre abrégé: Reumatologia
Pays: Poland
ID NLM: 20130190R
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
06
2020
accepted:
10
11
2020
entrez:
18
1
2021
pubmed:
19
1
2021
medline:
19
1
2021
Statut:
ppublish
Résumé
Despite the development of targeted therapies, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) remain the cornerstone of treatment of rheumatoid arthritis (RA). A literature search was conducted on treatment recommendations and relevant papers regarding new insights on therapeutics in rheumatoid arthritis. Methotrexate is considered the "anchor drug" due to its high efficacy as monotherapy and in combination with other conventional and targeted agents. Leflunomide and sulfasalazine are sound alternatives, whereas (hydroxy)chloroquine is primarily used in combination with other csDMARDs. Their use is encouraged in all treatment phases - in combination with targeted agents, and with other csDMARDs. Combining different csDMARDs is especially attractive in lower income settings given the evidence proving (almost) equal efficacy and safety of the csDMARD combination approach compared to the combination of targeted agents with a csDMARD. The aim of this review is to provide a clinically oriented insight into the pharmacology of each csDMARD and their place in treatment algorithms.
Identifiants
pubmed: 33456082
doi: 10.5114/reum.2020.101400
pii: 42589
pmc: PMC7792546
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
390-400Informations de copyright
Copyright: © 2020 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie.
Déclaration de conflit d'intérêts
The authors declare no conflict of interests.
Références
Presse Med. 2014 Jun;43(6 Pt 2):e167-80
pubmed: 24855048
Rheumatology (Oxford). 2012 Apr;51(4):670-8
pubmed: 22157597
Cochrane Database Syst Rev. 2000;(4):CD000959
pubmed: 11034691
Bull Hosp Jt Dis (2013). 2013;71 Suppl 1:S5-8
pubmed: 24219035
Ann Rheum Dis. 2016 Sep;75(9):1595-8
pubmed: 27091836
Nat Rev Nephrol. 2011 Oct 18;7(12):718-29
pubmed: 22009248
Rheumatology (Oxford). 2000 Jul;39(7):689-92
pubmed: 10908683
RMD Open. 2017 Jan 3;3(1):e000371
pubmed: 28123782
J Leukoc Biol. 2019 Nov;106(5):1063-1068
pubmed: 31313387
Lancet. 2017 Jul 29;390(10093):457-468
pubmed: 28629665
Ann Rheum Dis. 2014 Aug;73(8):1549-51
pubmed: 24728329
Arthritis Care Res (Hoboken). 2012 May;64(5):625-39
pubmed: 22473917
Rheumatology (Oxford). 2012 Jun;51 Suppl 4:iv9-13
pubmed: 22685274
Rheumatology (Oxford). 2013 Jun;52(6):1132-40
pubmed: 23401601
RMD Open. 2016 Jul 26;2(2):e000262
pubmed: 27493790
Arthritis Rheum. 2008 Jun 15;59(6):762-84
pubmed: 18512708
Ann Rheum Dis. 2014 Jan;73(1):3-5
pubmed: 24072562
Ann Intern Med. 2002 Nov 5;137(9):726-33
pubmed: 12416946
Ann Rheum Dis. 2016 May;75(5):795-810
pubmed: 26888948
Adv Ther. 2016 Mar;33(3):369-78
pubmed: 26846283
Clin Pharmacokinet. 2002;41(6):421-30
pubmed: 12074690
J Rheumatol. 2002 Oct;29(10):2077-83
pubmed: 12375315
Inflammopharmacology. 2015 Oct;23(5):231-69
pubmed: 26246395
Ann Rheum Dis. 2018 Apr;77(4):500-509
pubmed: 29222350
Ann Rheum Dis. 2018 Oct;77(10):1413-1420
pubmed: 29980576
Arthritis Care Res (Hoboken). 2019 Oct;71(10):1326-1335
pubmed: 30221485
Bull Hosp Jt Dis (2013). 2013;71 Suppl 1:S20-8
pubmed: 24219037
Ann Rheum Dis. 2010 Jan;69(1):88-96
pubmed: 19297346
Clin Rheumatol. 2010 Aug;29(8):913-20
pubmed: 20496042
Ann Rheum Dis. 2000 Nov;59(11):841-9
pubmed: 11053058
Ann Rheum Dis. 2018 Jan;77(1):98-103
pubmed: 28970215
Ann Rheum Dis. 2003 Oct;62(10):944-51
pubmed: 12972472
Adv Ther. 2018 Oct;35(10):1535-1563
pubmed: 30128641
Ann Rheum Dis. 2010 Jun;69(6):1004-9
pubmed: 20447954
Arthritis Rheumatol. 2017 Aug;69(8):1538-1551
pubmed: 28620948
Curr Opin Rheumatol. 2015 Mar;27(2):183-8
pubmed: 25603037
Ann Rheum Dis. 2017 Jun;76(6):960-977
pubmed: 28264816
Rheumatology (Oxford). 2012 Dec;51 Suppl 6:vi28-36
pubmed: 23221584
Rheumatology (Oxford). 2004 Jul;43(7):906-14
pubmed: 15113999
Ophthalmology. 2016 Jun;123(6):1386-94
pubmed: 26992838
Br Med J (Clin Res Ed). 1986 Aug 16;293(6544):420-3
pubmed: 2874863
Arthritis Rheumatol. 2016 Jan;68(1):1-26
pubmed: 26545940
Arthritis Rheum. 2005 Nov;52(11):3381-90
pubmed: 16258899
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S27-32
pubmed: 21044430
Br J Rheumatol. 1997 Mar;36(3):382-6
pubmed: 9133974
Ann Rheum Dis. 1993 Oct;52(10):711-5
pubmed: 7903034
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
Ann Rheum Dis. 2014 Mar;73(3):492-509
pubmed: 24161836
Nat Rev Rheumatol. 2015 May;11(5):276-89
pubmed: 25687177
BMJ. 2016 Apr 21;353:i1777
pubmed: 27102806
Ann Rheum Dis. 2009 Jul;68(7):1100-4
pubmed: 19060002
Clin Rheumatol. 2013 Feb;32(2):267-70
pubmed: 23179005
Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S179-85
pubmed: 14969073
Reumatologia. 2019;57(1):27-36
pubmed: 30858628